FILING ANALYSIS · TUESDAY, NOVEMBER 3
Faeth Therapeutics, Inc. FTH — 8-K: Results of Operations and Financial Condition
neutral
Faeth Therapeutics reported a net loss of $20.4 million and increased research and development expenses, but also announced the FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer, and expects topline results from the Phase 2 PIK-201 trial by year-end. The company's cash and cash equivalents increased to $174.8 million as of September 30,
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →